Context Therapeutics, Inc. (CNTX)

In the past six months, Context Therapeutics' stock price has fluctuated, reaching $1.55 on January 2, 2026, a 32.48% increase from $1.17 on January 6, 2025. The stock's 52-week range has been between $0.49 and $2.00. Key events include analyst coverage with "Buy" or "Overweight" recommendations from Jones Trading, Cantor Fitzgerald, and Guggenheim, among others. The consensus rating is a "Moderate Buy" with an average price target of $6.00. Context Therapeutics highlighted its CT-95 and CT-202 programs at the SITC Annual Meeting in November 2025 and reported its Q3 2025 results. The company also participated in investor conferences in October 2025. The CEO bought 100,000 shares. The company reported $94.4 million in cash at the end of 2024, expected to fund operations into 2027, but also reported an increased net loss of $26.7 million for 2024.

Information specifically detailing the demand seasonality for Context Therapeutics, Inc.'s products and services is not explicitly available. Demand for its products, once commercialized, would likely be driven by disease prevalence, treatment efficacy, and market access rather than traditional seasonal consumer patterns.

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumor treatment. Their lead product candidates include CTIM-76, an anti-Claudin 6 x anti-CD3 bispecific antibody; CT-95, a Mesothelin x CD3 bispecific TCE; and CT-202, a Nectin-4 x CD3 bispecific TCE designed to be active in the acidic tumor microenvironment. The first patient was dosed with CTIM-76 in January 2025, with initial clinical data expected in the first half of 2026. First patient dosing for CT-95 is expected in Q2 2025, with trial data in mid-2026. Regulatory filings to initiate a first-in-human trial for CT-202 are expected in the second quarter of 2026.

Context Therapeutics Inc. is headquartered in Philadelphia, Pennsylvania, United States. The company primarily conducts its clinical research in North America and is preparing for potential global expansion.

Context Therapeutics' brand reputation over the past year is generally positive, particularly within the investment community, with a consensus "Moderate Buy" rating from analysts. The stock has demonstrated "Very Strong" momentum. Progress in clinical programs, positive analyst coverage, a strengthened financial position due to a private placement, and presentations at scientific meetings have contributed to its reputation.

Context Therapeutics Inc. has significant institutional ownership, with 75.06% of its stock held by institutional shareholders, 6.45% by individuals, and 23.51% by retail investors. Major institutional owners include MPM BioImpact LLC, Avidity Partners Management LP, Nextech Invest Ltd, Deep Track Capital LP, Blue Owl Capital Holdings LP, Great Point Partners LLC, Franklin Resources Inc, Vanguard Group Inc, and Blackstone Inc. The largest individual shareholder is Martin A. Lehr.